טוען...
Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
Bendamustine (Treanda, Ribomustin) was recently approved by the US Food and Drug Administration (FDA) for treatment of patients with rituximab refractory indolent lymphoma and is expected to turn into a frontline therapy option for indolent lymphoma. This compound with amphoteric properties was desi...
שמור ב:
| מחבר ראשי: | |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Libertas Academica
2011
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3117628/ https://ncbi.nlm.nih.gov/pubmed/21695099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S6085 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|